Identification

Name
Citalopram
Accession Number
DB00215  (APRD00147)
Type
Small Molecule
Groups
Approved
Description

Citalopram belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). In spite of structural differences between compounds in this class, the SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be indicated before a clinical effect is noticed. SSRIs are potent inhibitors of serotonin reuptake in the neurons. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute usage, SSRIs inhibit serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The general clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction, and headache. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Citalopram is approved for treatment of depression. Unlabeled indications include mild dementia-associated agitation in nonpsychotic patients, smoking cessation, ethanol abuse, obsessive-compulsive disorder (OCD) in children, and diabetic neuropathy [5].

Structure
Thumb
Synonyms
  • Citadur
  • Nitalapram
External IDs
Lu 10-171
Product Ingredients
IngredientUNIICASInChI Key
Citalopram HydrobromideI1E9D14F3659729-32-7WIHMBLDNRMIGDW-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act CitalopramTablet30 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
Act CitalopramTablet40 mgOralActavis Pharma Company2004-01-21Not applicableCanada
Act CitalopramTablet20 mgOralActavis Pharma Company2004-01-21Not applicableCanada
CelexaTablet, film coated20 mg/1OralAllergan1998-07-17Not applicableUs
CelexaTablet, film coated40 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2011-11-172018-02-24Us
CelexaTablet40 mg/1OralPhysicians Total Care, Inc.2001-09-05Not applicableUs
CelexaTablet, film coated10 mg/1OralAllergan1998-07-17Not applicableUs
CelexaTablet, film coated40 mg/1OralAllergan1998-07-17Not applicableUs
CelexaTablet20 mg/1OralPhysicians Total Care, Inc.2000-11-28Not applicableUs
CelexaTablet10 mg/1OralPhysicians Total Care, Inc.2004-01-30Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-citalopramTablet20 mgOralAbbott2014-03-122015-12-31Canada
Abbott-citalopramTablet10 mgOralAbbott2014-03-172015-12-31Canada
Abbott-citalopramTablet40 mgOralAbbott2014-03-122015-12-31Canada
Accel-citalopram TabletsTablet10 mgOralAccel Pharma Inc2013-03-21Not applicableCanada
Accel-citalopram TabletsTablet40 mgOralAccel Pharma Inc2013-07-02Not applicableCanada
Accel-citalopram TabletsTablet20 mgOralAccel Pharma Inc2013-07-02Not applicableCanada
Ag-citalopramTablet40 mgOralAngita Pharma Inc.2014-09-14Not applicableCanada
Ag-citalopramTablet20 mgOralAngita Pharma Inc.2014-09-14Not applicableCanada
Ag-citalopramTablet10 mgOralAngita Pharma Inc.2014-08-14Not applicableCanada
Apo-citalopramTablet40 mgOralApotex Corporation2004-01-21Not applicableCanada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Sentralopram AM-10Citalopram Hydrobromide + CholineKitPhysician Therapeutics Llc2011-07-072016-10-13Us
International/Other Brands
Akarin / Celapram / Ciazil / Cilift / Cipram / Cipramil / Ciprapine / Citabax / Citalec / Citol / Citopam / Citox / Citrol / Dalsan / Elopram / Humorup / Oropram / Pramcit / Recital / Seropram / Talam / Talohexal / Temperax / Vodelax / Zentius / Zetalo
Categories
UNII
0DHU5B8D6V
CAS number
59729-33-8
Weight
Average: 324.3919
Monoisotopic: 324.163791509
Chemical Formula
C20H21FN2O
InChI Key
WSEQXVZVJXJVFP-UHFFFAOYSA-N
InChI
InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
IUPAC Name
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
SMILES
CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1

Pharmacology

Indication

For the treatment of depression. Off-label indications include: treatment of mild dementia-associated agitation in nonpsychotic patients, smoking cessation, ethanol abuse, obsessive-compulsive disorder (OCD) in children, and diabetic neuropathy [FDA Label].

Structured Indications
Pharmacodynamics

Citalopram belongs to a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). It is used to treat depression, anxiety, eating disorders and obsessive-compulsive disorder among other mood disorders. The antidepressant, anti-anxiety, and antibulimic actions of citalopram are linked to its inhibition of CNS central uptake of serotonin [FDA Label]. In vitro studies demonstrate that citalopram is a potent and selective inhibitor of neuronal serotonin reuptake and has weak effects on norepinephrine and dopamine central reuptake. The chronic administration of citalopram has been shown to downregulate central norepinephrine receptors, as has been noted with other drugs effective in the treatment of major depressive disorder. Citalopram does not inhibit monoamine oxidase [5].

Mechanism of action

The mechanism of action of citalopram results from its inhibition of CNS neuronal reuptake of serotonin (5-HT) [FDA Label]. Studies suggest that citalopram is a highly selective serotonin reuptake inhibitor (SSRI) with little effect on norepinephrine (NE) and dopamine (DA) central reuptake [FDA Label].

Citalopram binds with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs [FDA Label].

TargetActionsOrganism
ASodium-dependent serotonin transporter
inhibitor
Human
UHistamine H1 receptor
binder
Human
UAlpha-1A adrenergic receptor
binder
Human
UMuscarinic acetylcholine receptor M1
binder
Human
U5-hydroxytryptamine receptor 2C
antagonist
Human
Absorption

Rapidly and well absorbed from the GI tract. Peak plasma concentrations occur within 4 hours of a single orally administered dose. Bioavailability is 80% following oral administration. Food does not affect absorption [FDA Label].

Volume of distribution
  • 12 L/kg [FDA Label] Citalopram is highly lipophilic and likely widely distributed throughout the body, including the blood-brain-barrier. However, its metabolite, demethylcitalopram does not cross the blood-brain-barrier well [FDA Label]
Protein binding

Citalopram, dimethylcitalopram, and didemethylcitalopram is 80% bound to plasma proteins [FDA Label].

Metabolism

Citalopram is metabolized mainly in the liver via N-demethylation to its main metabolite, demethylcitalopram. Other metabolites include didemethylcitalopram, citalopram N-oxide, and a deaminated propionic acid derivative. However, the drug in plasma is found mainly unchanged as citalopram. Cytochrome P450 (CYP) 3A4 and 2C19 isozymes appear to be principally involved in producing demethylcitalopram. Demethylcitalopram appears to be further N-demethylated by CYP2D6 to didemethylcitalopram. Citalopram metabolites possess little pharmacologic activity in comparison to their parent compound and do not likely contribute to the clinical effect of the drug [5].

Citalopram and its N-demethylated metabolites exist as a racemic mixture but its effects are largely due to the S-enantiomer, S-citalopram and S-demthylcitalopram.

After a single dose of citalopram, peak blood concentrations occur at approximately 4 hours. The bioavailability of this drug was about 80%, compared to an IV dose [FDA Label]. The volume of distribution of citalopram is about 12 L/kg and c

Route of elimination

12-23% of an oral dose of citalopram is found unchanged in the urine, while 10% of the dose is found in the faeces [FDA Label]

Half life

35 hours [FDA Label].

Clearance

The systemic clearance of citalopram is 330 mL/min, with approximately 20% renal clearance [FDA Label]

Toxicity

Symptoms of toxicity include dizziness, sweating, nausea, vomiting, tremor, somnolence, and sinus tachycardia. Rarely, symptoms included amnesia, confusion, coma, convulsions, hyperventilation, cyanosis, rhabdomyolysis, and ECG changes (including QTc prolongation, nodal rhythm, ventricular arrhythmia, and extremely rare cases of cardiac torsade de pointes) may occur. Acute renal failure has been a rare occurrence [5].

In cases of overdose, establish and maintain the airway to ensure adequate ventilation and oxygen delivery. Due to the large volume of distribution of citalopram, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. Gastric evacuation by lavage and use of activated charcoal should be considered. Careful observation and cardiac and vital sign monitoring are advised, in addition to supportive care. With the large volume of distribution of citalopram, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit [FDA Label].

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Citalopram Action PathwayDrug action
Citalopram Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Glutamate receptor ionotropic, kainate 2---(C;C)C Allele, homozygoteADR Directly StudiedPatients with this genotype have increased frequency of suicidal ideation with citalopramDetails
Glutamate receptor 3---(G;G) / (G;A)G alleleADR Directly StudiedPatients with this genotype have increased frequency of suicidal ideation with citalopramDetails
Multidrug resistance protein 1---(C;C) / (C;T)C AlleleEffect Directly StudiedPatients with this genotype have an increased likelihood of remission when using citalopram to treat major depressive disorderDetails
5-hydroxytryptamine receptor 2A---(A;A)A AlleleEffect Directly StudiedPatients with this genotype have an increased likelihood of responding to citalopram when treating major depressive disorderDetails
Glutamate receptor ionotropic, kainate 4---(C;C)C AlleleEffect Directly StudiedPatients with this genotype have an increased likelihood of responding to citalopram when treating major depressive disorderDetails
Cyclic AMP-responsive element-binding protein 1---(T;T)T allele, homozygousADR Directly StudiedMale patients with this genotype have an increased risk of (condition: suicide) with (drug: citalopram).Details
Cytochrome P450 2C19CYP2C19*2ANot Available681G>AADR InferredPoor drug metabolizer, increased risk of QT prolongation. For individual with two non-functional alleles, dose reduction or alternative drug recommended.Details
Cytochrome P450 2C19CYP2C19*2BNot Available681G>AADR InferredPoor drug metabolizer, increased risk of QT prolongation. For individual with two non-functional alleles, dose reduction or alternative drug recommended.Details
Cytochrome P450 2C19CYP2C19*3Not Available636G>AADR InferredPoor drug metabolizer, increased risk of QT prolongation. For individual with two non-functional alleles, dose reduction or alternative drug recommended.Details
Cytochrome P450 2C19CYP2C19*4Not Available1A>GADR InferredPoor drug metabolizer, increased risk of QT prolongation. For individual with two non-functional alleles, dose reduction or alternative drug recommended.Details
Cytochrome P450 2C19CYP2C19*5Not Available1297C>TADR InferredPoor drug metabolizer, increased risk of QT prolongation. For individual with two non-functional alleles, dose reduction or alternative drug recommended.Details
Cytochrome P450 2C19CYP2C19*6Not Available395G>AADR InferredPoor drug metabolizer, increased risk of QT prolongation. For individual with two non-functional alleles, dose reduction or alternative drug recommended.Details
Cytochrome P450 2C19CYP2C19*7Not Available19294T>AADR InferredPoor drug metabolizer, increased risk of QT prolongation. For individual with two non-functional alleles, dose reduction or alternative drug recommended.Details
Cytochrome P450 2C19CYP2C19*22Not Available557G>C / 991A>GADR InferredPoor drug metabolizer, increased risk of QT prolongation. For individual with two non-functional alleles, dose reduction or alternative drug recommended.Details
Cytochrome P450 2C19CYP2C19*24Not Available99C>T / 991A>G  … show all ADR InferredPoor drug metabolizer, increased risk of QT prolongation. For individual with two non-functional alleles, dose reduction or alternative drug recommended.Details
Cytochrome P450 2C19CYP2C19*35Not Available12662A>GADR InferredPoor drug metabolizer, increased risk of QT prolongation. For individual with two non-functional alleles, dose reduction or alternative drug recommended.Details

Interactions

Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Citalopram.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Citalopram.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Citalopram.Experimental
AbirateroneThe serum concentration of Citalopram can be increased when it is combined with Abiraterone.Approved
AcarboseCitalopram may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Citalopram.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Citalopram.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Citalopram.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Citalopram.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Acetophenazine.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Citalopram.Approved
Acetylsalicylic acidCitalopram may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Citalopram.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Citalopram.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Citalopram.Approved
AgomelatineThe serum concentration of Agomelatine can be increased when it is combined with Citalopram.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Citalopram.Approved, Investigational
AlaproclateCitalopram may increase the serotonergic activities of Alaproclate.Experimental
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Citalopram.Approved, Vet Approved
AlbiglutideCitalopram may increase the hypoglycemic activities of Albiglutide.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Citalopram.Vet Approved
AlfentanilAlfentanil may increase the serotonergic activities of Citalopram.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Citalopram.Approved, Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Citalopram.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Citalopram is combined with Almotriptan.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Citalopram.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Citalopram.Approved, Withdrawn
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Citalopram.Experimental, Illicit
AlphaprodineAlphaprodine may increase the serotonergic activities of Citalopram.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Citalopram.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Citalopram.Approved, Withdrawn
AmantadineAmantadine may increase the QTc-prolonging activities of Citalopram.Approved
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Citalopram.Approved, Investigational
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Citalopram.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Citalopram.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Citalopram.Approved
AmiodaroneThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Citalopram.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Citalopram.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Citalopram.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Citalopram.Approved
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Citalopram.Approved, Vet Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Citalopram.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Citalopram is combined with Amphetamine.Approved, Illicit, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Citalopram.Approved, Investigational
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Citalopram.Approved, Investigational
AnagrelideThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Anagrelide.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Citalopram.Approved, Investigational
ApalutamideThe serum concentration of Citalopram can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe metabolism of Apixaban can be decreased when combined with Citalopram.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
AprepitantThe serum concentration of Citalopram can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Citalopram.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Citalopram.Approved, Investigational
ArmodafinilThe serum concentration of Citalopram can be increased when it is combined with Armodafinil.Approved, Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Citalopram.Approved
AsenapineThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Citalopram.Approved, Withdrawn
AsunaprevirThe metabolism of Asunaprevir can be decreased when combined with Citalopram.Approved, Investigational, Withdrawn
AtazanavirThe metabolism of Citalopram can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Citalopram.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Citalopram.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Citalopram.Investigational, Vet Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Citalopram.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Citalopram.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Citalopram.Approved
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Citalopram.Investigational
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Citalopram.Illicit
BedaquilineBedaquiline may increase the QTc-prolonging activities of Citalopram.Approved
BendamustineThe metabolism of Bendamustine can be decreased when combined with Citalopram.Approved, Investigational
BendroflumethiazideCitalopram may increase the hyponatremic activities of Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Citalopram is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Citalopram.Approved, Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Citalopram.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Citalopram.Approved, Investigational
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Citalopram.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Citalopram.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Citalopram.Approved, Withdrawn
BetaxololThe metabolism of Betaxolol can be decreased when combined with Citalopram.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Citalopram.Approved, Investigational
BezitramideBezitramide may increase the serotonergic activities of Citalopram.Experimental, Illicit, Withdrawn
BifeprunoxThe risk or severity of adverse effects can be increased when Citalopram is combined with Bifeprunox.Investigational
BioallethrinThe metabolism of Bioallethrin can be decreased when combined with Citalopram.Approved, Experimental
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Citalopram.Approved
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Citalopram.Investigational
BoceprevirThe metabolism of Citalopram can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe serum concentration of Citalopram can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Citalopram can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Citalopram.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Citalopram.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Citalopram.Approved, Investigational
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Citalopram.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Citalopram.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Citalopram is combined with Brofaromine.Experimental
BromazepamThe metabolism of Bromazepam can be decreased when combined with Citalopram.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Citalopram.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Citalopram is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Citalopram.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Citalopram.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Citalopram.Approved, Investigational, Withdrawn
BufuralolThe metabolism of Bufuralol can be decreased when combined with Citalopram.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Citalopram.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Citalopram.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Citalopram.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
BuspironeBuspirone may increase the serotonergic activities of Citalopram.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Citalopram.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Citalopram.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Citalopram.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Citalopram.Approved, Withdrawn
ButaperazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Citalopram.Approved, Illicit
ButorphanolButorphanol may increase the serotonergic activities of Citalopram.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Citalopram is combined with Cabergoline.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Citalopram.Approved
CanagliflozinCitalopram may increase the hypoglycemic activities of Canagliflozin.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Citalopram.Investigational
CannabidiolThe metabolism of Cannabidiol can be decreased when combined with Citalopram.Approved, Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Citalopram.Approved
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Citalopram.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Citalopram.Approved
CarfentanilCarfentanil may increase the serotonergic activities of Citalopram.Illicit, Investigational, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Citalopram.Approved, Investigational
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Citalopram.Approved
CarmustineThe metabolism of Carmustine can be decreased when combined with Citalopram.Approved, Investigational
CaroxazoneThe risk or severity of adverse effects can be increased when Citalopram is combined with Caroxazone.Withdrawn
CarteololThe metabolism of Carteolol can be decreased when combined with Citalopram.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Citalopram.Approved, Investigational
CelecoxibCitalopram may increase the antiplatelet activities of Celecoxib.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Citalopram.Approved, Investigational, Vet Approved
CeritinibThe serum concentration of Citalopram can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Citalopram.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Citalopram.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Citalopram.Approved, Illicit, Investigational, Vet Approved
ChloramphenicolThe serum concentration of Citalopram can be increased when it is combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Citalopram.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Citalopram.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Citalopram.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Citalopram.Approved, Investigational, Vet Approved
ChlorothiazideCitalopram may increase the hyponatremic activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Citalopram.Approved
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorproethazine is combined with Citalopram.Experimental
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Citalopram.Approved, Investigational, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Citalopram.Approved, Investigational
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Citalopram.Approved, Investigational, Withdrawn
ChlorthalidoneCitalopram may increase the hyponatremic activities of Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Citalopram.Approved
CholecalciferolThe serum concentration of Citalopram can be increased when it is combined with Cholecalciferol.Approved, Nutraceutical
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Citalopram.Approved, Investigational
CimetidineThe serum concentration of Citalopram can be increased when it is combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Citalopram can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Citalopram.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Citalopram.Approved, Investigational
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
CisaprideThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Cisapride.Approved, Investigational, Withdrawn
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Citalopram.Approved
ClemastineThe metabolism of Citalopram can be decreased when combined with Clemastine.Approved, Investigational
ClenbuterolThe metabolism of Clenbuterol can be decreased when combined with Citalopram.Approved, Investigational, Vet Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Citalopram.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Citalopram.Approved
ClobazamThe metabolism of Citalopram can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Citalopram.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Citalopram.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Citalopram.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Citalopram.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Citalopram.Experimental
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Citalopram resulting in a loss in efficacy.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Citalopram.Approved, Illicit
ClorindioneCitalopram may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Citalopram.Experimental
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Citalopram.Approved, Illicit
ClotrimazoleThe serum concentration of Citalopram can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Citalopram.Approved
CobicistatThe serum concentration of Citalopram can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Citalopram can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Citalopram.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Citalopram.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Citalopram.Approved, Investigational
Conjugated estrogensThe metabolism of Conjugated estrogens can be decreased when combined with Citalopram.Approved
CrizotinibCrizotinib may increase the QTc-prolonging activities of Citalopram.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Citalopram.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Citalopram.Approved
CyclopenthiazideCitalopram may increase the hyponatremic activities of Cyclopenthiazide.Experimental
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Citalopram.Approved, Investigational
CyclopropaneThe risk or severity of adverse effects can be increased when Cyclopropane is combined with Citalopram.Experimental
CyclosporineThe metabolism of Citalopram can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe therapeutic efficacy of Citalopram can be decreased when used in combination with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Citalopram can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Citalopram.Approved
DabrafenibThe serum concentration of Citalopram can be decreased when it is combined with Dabrafenib.Approved, Investigational
DacarbazineThe metabolism of Dacarbazine can be decreased when combined with Citalopram.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Citalopram.Approved, Investigational
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Citalopram.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Citalopram.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Citalopram.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Citalopram.Approved, Investigational
DarifenacinThe metabolism of Citalopram can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Citalopram can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Citalopram.Approved
DasatinibThe serum concentration of Citalopram can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Citalopram.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Citalopram.Approved, Investigational
DeferasiroxThe serum concentration of Citalopram can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Citalopram.Approved
DelamanidCitalopram may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
DelavirdineThe serum concentration of Citalopram can be increased when it is combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Citalopram.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Citalopram.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Citalopram.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Citalopram.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Citalopram is combined with Desmopressin.Approved
DesvenlafaxineDesvenlafaxine may increase the serotonergic activities of Citalopram.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Citalopram.Vet Approved
DeutetrabenazineCitalopram may increase the QTc-prolonging activities of Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Citalopram.Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Citalopram.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Citalopram.Approved, Illicit, Investigational, Withdrawn
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Citalopram.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Citalopram.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Citalopram.Approved, Investigational
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Citalopram.Approved, Illicit
DextromethorphanCitalopram may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideDextromoramide may increase the serotonergic activities of Citalopram.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Citalopram.Approved, Illicit, Investigational, Withdrawn
DezocineDezocine may increase the serotonergic activities of Citalopram.Approved, Investigational
DiazepamThe metabolism of Diazepam can be decreased when combined with Citalopram.Approved, Illicit, Investigational, Vet Approved
DibenzepinThe risk or severity of adverse effects can be increased when Dibenzepin is combined with Citalopram.Experimental
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Citalopram.Approved, Vet Approved
DicoumarolCitalopram may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Citalopram.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Citalopram.Approved, Illicit
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Citalopram.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Citalopram is combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Citalopram.Experimental, Illicit
DihydromorphineDihydromorphine may increase the serotonergic activities of Citalopram.Experimental, Illicit
DiltiazemThe metabolism of Citalopram can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Citalopram.Approved
DinoprostoneThe metabolism of Dinoprostone can be decreased when combined with Citalopram.Approved
DiphenadioneCitalopram may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Citalopram.Approved, Illicit
DisopyramideThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Citalopram.Experimental
DofetilideThe risk or severity of QTc prolongation can be increased when Dofetilide is combined with Citalopram.Approved, Investigational
DolasetronDolasetron may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
DomperidoneThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Domperidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Citalopram.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Citalopram.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Citalopram.Vet Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Citalopram.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Citalopram.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Citalopram.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Citalopram.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Citalopram.Approved, Investigational
DoxycyclineThe metabolism of Citalopram can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Citalopram.Approved, Vet Approved
DPDPEDPDPE may increase the serotonergic activities of Citalopram.Experimental
DronabinolThe metabolism of Dronabinol can be decreased when combined with Citalopram.Approved, Illicit
DronedaroneThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Citalopram.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Citalopram.Experimental, Illicit
DulaglutideCitalopram may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Citalopram.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Citalopram.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Citalopram.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Citalopram.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Citalopram.Approved
EfavirenzThe serum concentration of Citalopram can be increased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Citalopram is combined with Eletriptan.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Citalopram.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Citalopram.Investigational
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Citalopram.Approved
EmpagliflozinCitalopram may increase the hypoglycemic activities of Empagliflozin.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Citalopram.Approved, Investigational
EncainideThe metabolism of Encainide can be decreased when combined with Citalopram.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Citalopram.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Citalopram.Approved, Investigational, Vet Approved
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Citalopram.Approved, Investigational
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Citalopram.Approved, Investigational
EnzalutamideThe serum concentration of Citalopram can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Citalopram.Approved, Investigational
EpitizideCitalopram may increase the hyponatremic activities of Epitizide.Experimental
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Citalopram is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Citalopram is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Citalopram is combined with Ergotamine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Citalopram.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Citalopram.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Citalopram can be increased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Citalopram.Investigational
EsomeprazoleThe serum concentration of Citalopram can be increased when it is combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Citalopram.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Citalopram.Approved, Investigational, Vet Approved
Estradiol acetateThe metabolism of Estradiol acetate can be decreased when combined with Citalopram.Approved, Investigational, Vet Approved
Estradiol benzoateThe metabolism of Estradiol benzoate can be decreased when combined with Citalopram.Approved, Investigational, Vet Approved
Estradiol cypionateThe metabolism of Estradiol cypionate can be decreased when combined with Citalopram.Approved, Investigational, Vet Approved
Estradiol dienanthateThe metabolism of Estradiol dienanthate can be decreased when combined with Citalopram.Approved, Investigational, Vet Approved
Estradiol valerateThe metabolism of Estradiol valerate can be decreased when combined with Citalopram.Approved, Investigational, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Citalopram.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Citalopram.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Citalopram.Approved, Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Citalopram.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Citalopram.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Citalopram.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Citalopram.Approved
Ethyl biscoumacetateCitalopram may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Citalopram.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Citalopram.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Citalopram.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Citalopram.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Citalopram.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Citalopram.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Citalopram.Approved
EtodolacCitalopram may increase the antiplatelet activities of Etodolac.Approved, Investigational, Vet Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Citalopram.Approved
EtoperidoneEtoperidone may increase the serotonergic activities of Citalopram.Withdrawn
EtoposideThe metabolism of Etoposide can be decreased when combined with Citalopram.Approved
EtoricoxibCitalopram may increase the antiplatelet activities of Etoricoxib.Approved, Investigational
EtorphineEtorphine may increase the serotonergic activities of Citalopram.Illicit, Vet Approved
EtravirineThe serum concentration of Citalopram can be increased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Citalopram.Approved
ExenatideCitalopram may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
FamotidineFamotidine may increase the QTc-prolonging activities of Citalopram.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Citalopram.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Citalopram.Approved, Illicit, Withdrawn
FenfluramineCitalopram may increase the serotonergic activities of Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Citalopram is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Citalopram.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Citalopram.Approved, Investigational
FingolimodFingolimod may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Citalopram.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Citalopram.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Citalopram.Experimental
FluconazoleFluconazole may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Citalopram.Approved, Illicit
FluindioneCitalopram may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Citalopram.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Citalopram.Approved, Illicit
FluorouracilThe metabolism of Fluorouracil can be decreased when combined with Citalopram.Approved
FluoxetineThe serum concentration of Citalopram can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Citalopram.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Citalopram.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Citalopram.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Citalopram.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Citalopram.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Citalopram.Approved
FluvoxamineThe serum concentration of Citalopram can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
FosamprenavirThe metabolism of Citalopram can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Citalopram can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Citalopram.Approved
FosphenytoinThe metabolism of Citalopram can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Citalopram.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Citalopram is combined with Frovatriptan.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Citalopram.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Citalopram can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Citalopram.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Citalopram.Approved, Investigational
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Citalopram.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Citalopram.Approved, Illicit, Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Citalopram.Approved, Investigational
GemfibrozilThe serum concentration of Citalopram can be increased when it is combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
GenisteinThe metabolism of Genistein can be decreased when combined with Citalopram.Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Citalopram.Investigational
GliclazideThe metabolism of Gliclazide can be decreased when combined with Citalopram.Approved
GlimepirideCitalopram may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideCitalopram may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Citalopram.Approved, Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Citalopram.Approved, Illicit
GlyburideThe metabolism of Glyburide can be decreased when combined with Citalopram.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Citalopram.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Citalopram.Approved, Investigational, Withdrawn
GuanabenzThe metabolism of Guanabenz can be decreased when combined with Citalopram.Approved, Investigational
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Citalopram.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Citalopram.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Citalopram.Approved
HaloperidolHaloperidol may increase the QTc-prolonging activities of Citalopram.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Citalopram.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Citalopram is combined with Harmaline.Experimental
HeroinHeroin may increase the serotonergic activities of Citalopram.Approved, Illicit, Investigational
HesperetinThe metabolism of Hesperetin can be decreased when combined with Citalopram.Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Citalopram.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Citalopram.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Hydracarbazine.Experimental
HydrochlorothiazideCitalopram may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Citalopram.Approved, Illicit
HydroflumethiazideCitalopram may increase the hyponatremic activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Citalopram.Approved, Illicit
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Citalopram.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Citalopram.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Citalopram.Approved
IbutilideThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Ibutilide.Approved
IcotinibThe metabolism of Icotinib can be decreased when combined with Citalopram.Approved, Investigational
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Citalopram.Approved
IdelalisibThe metabolism of Citalopram can be decreased when combined with Idelalisib.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Citalopram.Approved
IloperidoneThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Iloperidone.Approved
ImatinibThe metabolism of Citalopram can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Citalopram.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Citalopram.Approved, Investigational
IndacaterolIndacaterol may increase the QTc-prolonging activities of Citalopram.Approved
IndalpineIndalpine may increase the serotonergic activities of Citalopram.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Citalopram.Approved
IndinavirThe serum concentration of Citalopram can be increased when it is combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Citalopram.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Citalopram.Approved, Investigational
Insulin AspartCitalopram may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirCitalopram may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineCitalopram may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineCitalopram may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanCitalopram may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproCitalopram may increase the hypoglycemic activities of Insulin Lispro.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Citalopram.Approved, Investigational
Ioflupane I-123Citalopram may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Citalopram.Approved
IprindoleThe risk or severity of adverse effects can be increased when Iprindole is combined with Citalopram.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Citalopram is combined with Iproclozide.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Citalopram.Withdrawn
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Citalopram.Approved, Investigational
IsavuconazoleThe serum concentration of Citalopram can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Citalopram can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe therapeutic efficacy of Citalopram can be increased when used in combination with Isocarboxazid.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Citalopram.Approved, Vet Approved
IsoniazidThe serum concentration of Citalopram can be increased when it is combined with Isoniazid.Approved, Investigational
IsradipineIsradipine may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
ItraconazoleThe metabolism of Citalopram can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineCitalopram may increase the QTc-prolonging activities of Ivabradine.Approved
IvacaftorThe serum concentration of Citalopram can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Citalopram.Approved, Investigational
KetamineThe metabolism of Ketamine can be decreased when combined with Citalopram.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Citalopram.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Citalopram.Approved, Investigational
KetoconazoleThe serum concentration of Citalopram can be increased when it is combined with Ketoconazole.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Citalopram.Approved, Nutraceutical, Withdrawn
LabetalolThe metabolism of Labetalol can be decreased when combined with Citalopram.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Citalopram.Approved, Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Citalopram.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Citalopram.Approved
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Citalopram.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
LetermovirThe metabolism of Letermovir can be decreased when combined with Citalopram.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Citalopram.Approved, Investigational
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Citalopram.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Citalopram.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Citalopram.Approved
LevodopaThe metabolism of Levodopa can be decreased when combined with Citalopram.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Citalopram.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the serotonergic activities of Citalopram.Approved, Investigational
LevorphanolLevorphanol may increase the serotonergic activities of Citalopram.Approved
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Citalopram.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Citalopram.Approved, Vet Approved
LinezolidLinezolid may increase the serotonergic activities of Citalopram.Approved, Investigational
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Citalopram.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Citalopram.Approved
LiraglutideCitalopram may increase the hypoglycemic activities of Liraglutide.Approved
LisurideThe metabolism of Lisuride can be decreased when combined with Citalopram.Approved, Investigational
LithiumLithium may increase the serotonergic activities of Citalopram.Approved
LobeglitazoneThe serum concentration of Citalopram can be increased when it is combined with Lobeglitazone.Approved, Investigational
LofentanilLofentanil may increase the serotonergic activities of Citalopram.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Lofepramine is combined with Citalopram.Experimental
LomefloxacinThe metabolism of Lomefloxacin can be decreased when combined with Citalopram.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Citalopram.Approved, Investigational
LoperamideThe metabolism of Loperamide can be decreased when combined with Citalopram.Approved
LopinavirThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Citalopram.Experimental
LoratadineThe metabolism of Loratadine can be decreased when combined with Citalopram.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Citalopram.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Citalopram is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Citalopram.Approved
LorpiprazoleThe serum concentration of Citalopram can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe metabolism of Citalopram can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Citalopram.Approved
LuliconazoleThe serum concentration of Citalopram can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Citalopram can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Lumefantrine.Approved
LumiracoxibCitalopram may increase the antiplatelet activities of Lumiracoxib.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Citalopram.Approved, Investigational
MacimorelinCitalopram may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
MacitentanThe metabolism of Macitentan can be decreased when combined with Citalopram.Approved
Magnesium sulfateThe risk or severity of adverse effects can be increased when Magnesium sulfate is combined with Citalopram.Approved, Investigational, Vet Approved
MalathionThe metabolism of Malathion can be decreased when combined with Citalopram.Approved, Investigational
ManidipineThe metabolism of Citalopram can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Citalopram.Experimental
MecaserminCitalopram may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Citalopram.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Citalopram.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Citalopram.Vet Approved
Medical CannabisThe metabolism of Medical Cannabis can be decreased when combined with Citalopram.Experimental, Investigational
MefloquineMefloquine may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
MelatoninThe metabolism of Melatonin can be decreased when combined with Citalopram.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Citalopram.Approved, Investigational
MenadioneThe metabolism of Menadione can be decreased when combined with Citalopram.Approved, Nutraceutical
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Citalopram.Investigational, Withdrawn
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Citalopram.Approved, Vet Approved
MeprobamateThe metabolism of Meprobamate can be decreased when combined with Citalopram.Approved, Illicit
MeptazinolMeptazinol may increase the serotonergic activities of Citalopram.Experimental
MequitazineThe metabolism of Mequitazine can be decreased when combined with Citalopram.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Citalopram.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Citalopram.Approved
MetforminCitalopram may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Citalopram.Approved
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Citalopram.Approved, Illicit
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Citalopram.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Citalopram.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Citalopram.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Citalopram.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Citalopram.Approved
MethotrimeprazineThe metabolism of Citalopram can be decreased when combined with Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Citalopram.Approved, Investigational, Vet Approved
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Citalopram.Approved
MethyclothiazideCitalopram may increase the hyponatremic activities of Methyclothiazide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Citalopram.Experimental
Methylene blueCitalopram may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Citalopram.Approved, Investigational
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Citalopram.Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Citalopram.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Citalopram.Approved, Illicit, Withdrawn
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Citalopram.Approved, Investigational
MetolazoneCitalopram may increase the hyponatremic activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Citalopram.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Citalopram.Approved
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Citalopram.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Citalopram.Approved, Investigational
MianserinThe metabolism of Mianserin can be decreased when combined with Citalopram.Approved, Investigational
MidazolamThe metabolism of Midazolam can be decreased when combined with Citalopram.Approved, Illicit
MidostaurinThe metabolism of Citalopram can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneCitalopram may increase the QTc-prolonging activities of Mifepristone.Approved, Investigational
MiglitolCitalopram may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranMilnacipran may increase the serotonergic activities of Citalopram.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Citalopram is combined with Minaprine.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Citalopram.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Citalopram.Approved
MitotaneThe serum concentration of Citalopram can be decreased when it is combined with Mitotane.Approved
MoclobemideThe serum concentration of Citalopram can be increased when it is combined with Moclobemide.Approved, Investigational
ModafinilThe serum concentration of Citalopram can be increased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Citalopram.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Citalopram.Approved
MoperoneThe risk or severity of adverse effects can be increased when Citalopram is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Citalopram.Approved, Investigational, Withdrawn
MorphineThe metabolism of Morphine can be decreased when combined with Citalopram.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Citalopram is combined with Mosapramine.Experimental
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
MuraglitazarThe metabolism of Muraglitazar can be decreased when combined with Citalopram.Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Citalopram.Approved, Investigational
NabiximolsThe metabolism of Nabiximols can be decreased when combined with Citalopram.Approved, Investigational
NabumetoneCitalopram may increase the antiplatelet activities of Nabumetone.Approved
NalbuphineNalbuphine may increase the serotonergic activities of Citalopram.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Citalopram.Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Citalopram.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Citalopram is combined with Naratriptan.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Citalopram.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Citalopram.Approved, Investigational
NefazodoneThe metabolism of Citalopram can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Citalopram can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Citalopram can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Citalopram can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Citalopram.Withdrawn
NicardipineThe serum concentration of Citalopram can be increased when it is combined with Nicardipine.Approved, Investigational
NicergolineThe metabolism of Nicergoline can be decreased when combined with Citalopram.Approved, Investigational
NicomorphineNicomorphine may increase the serotonergic activities of Citalopram.Experimental
NicotineThe metabolism of Nicotine can be decreased when combined with Citalopram.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Citalopram.Approved
NilotinibThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Nilotinib.Approved, Investigational
NilutamideThe metabolism of Nilutamide can be decreased when combined with Citalopram.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Citalopram.Approved
Nitric OxideThe metabolism of Nitric Oxide can be decreased when combined with Citalopram.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Citalopram.Approved, Investigational, Vet Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Citalopram.Approved, Vet Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Citalopram.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Citalopram.Approved, Investigational
NormethadoneNormethadone may increase the serotonergic activities of Citalopram.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Citalopram.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Citalopram is combined with Octamoxin.Withdrawn
OctreotideOctreotide may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Citalopram.Approved
OlanzapineCitalopram may increase the serotonergic activities of Olanzapine.Approved, Investigational
OlaparibThe metabolism of Citalopram can be decreased when combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Citalopram.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Citalopram.Approved
OmeprazoleThe serum concentration of Citalopram can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Citalopram.Approved
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Citalopram.Investigational
OpiumOpium may increase the serotonergic activities of Citalopram.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Citalopram.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Citalopram.Investigational
OsimertinibThe serum concentration of Citalopram can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Citalopram.Approved, Investigational
OxaliplatinThe metabolism of Oxaliplatin can be decreased when combined with Citalopram.Approved, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Citalopram.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Citalopram.Approved, Investigational
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Citalopram.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Citalopram.Approved
OxtriphyllineThe metabolism of Oxtriphylline can be decreased when combined with Citalopram.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Citalopram.Approved, Investigational
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Citalopram.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Citalopram.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Citalopram is combined with Oxypertine.Experimental
OxytocinOxytocin may increase the QTc-prolonging activities of Citalopram.Approved, Vet Approved
PalbociclibThe serum concentration of Citalopram can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Citalopram.Approved, Investigational
PanobinostatThe serum concentration of Citalopram can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Citalopram can be increased when it is combined with Pantoprazole.Approved
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Citalopram.Approved, Investigational
ParecoxibCitalopram may increase the antiplatelet activities of Parecoxib.Approved
PargylinePargyline may increase the serotonergic activities of Citalopram.Approved
ParoxetineThe metabolism of Citalopram can be decreased when combined with Paroxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Citalopram.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Citalopram.Approved
Peginterferon alfa-2bThe serum concentration of Citalopram can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Citalopram.Experimental
PentamidinePentamidine may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
PentazocinePentazocine may increase the serotonergic activities of Citalopram.Approved, Vet Approved
PentobarbitalThe metabolism of Citalopram can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoxifyllineThe metabolism of Pentoxifylline can be decreased when combined with Citalopram.Approved, Investigational
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Citalopram.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Citalopram.Approved, Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Citalopram.Approved
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Citalopram.Approved, Investigational
PermethrinThe metabolism of Permethrin can be decreased when combined with Citalopram.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Citalopram.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Citalopram.Approved
PethidineThe risk or severity of adverse effects can be increased when Citalopram is combined with Pethidine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Citalopram.Withdrawn
PhenazocinePhenazocine may increase the serotonergic activities of Citalopram.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Citalopram is combined with Phenelzine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Citalopram.Approved, Investigational, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Citalopram.Experimental
PhenindioneCitalopram may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Citalopram can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidinePhenoperidine may increase the serotonergic activities of Citalopram.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Citalopram.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Phenoxypropazine.Withdrawn
PhenprocoumonCitalopram may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenytoinThe metabolism of Citalopram can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Pimozide.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Citalopram.Approved, Investigational
PioglitazoneCitalopram may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Citalopram.Approved, Investigational
PiperaquineThe metabolism of Piperaquine can be decreased when combined with Citalopram.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Citalopram.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Citalopram.Approved, Investigational
PirfenidoneThe serum concentration of Pirfenidone can be increased when it is combined with Citalopram.Approved, Investigational
PiritramidePiritramide may increase the serotonergic activities of Citalopram.Approved, Investigational
PirlindolePirlindole may increase the serotonergic activities of Citalopram.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Citalopram.Approved, Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Citalopram.Approved
PodofiloxThe metabolism of Podofilox can be decreased when combined with Citalopram.Approved
PolythiazideCitalopram may increase the hyponatremic activities of Polythiazide.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Citalopram.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Citalopram.Approved, Investigational
PosaconazoleThe metabolism of Citalopram can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideCitalopram may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Citalopram.Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Citalopram.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Citalopram.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Citalopram.Approved, Investigational, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Citalopram.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Citalopram.Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Citalopram.Approved
PrimidoneThe metabolism of Citalopram can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Citalopram.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Procarbazine.Approved, Investigational
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Citalopram.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Citalopram.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Citalopram.Approved
PromazinePromazine may increase the QTc-prolonging activities of Citalopram.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
PropafenoneThe serum concentration of Citalopram can be increased when it is combined with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Citalopram.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Citalopram.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Citalopram.Approved, Investigational
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Citalopram.Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Citalopram.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Citalopram.Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Citalopram.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Citalopram is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Citalopram.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Citalopram.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Citalopram.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Citalopram.Investigational
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Citalopram.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Citalopram.Approved, Investigational
QuazepamThe metabolism of Quazepam can be decreased when combined with Citalopram.Approved, Illicit
QuetiapineThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Quetiapine.Approved
QuinethazoneCitalopram may increase the hyponatremic activities of Quinethazone.Approved
QuinidineThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Quinidine.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Citalopram.Experimental
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Citalopram.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Citalopram.Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Citalopram.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Citalopram.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Citalopram.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Citalopram is combined with Rasagiline.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Citalopram.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Citalopram.Approved, Withdrawn
RepaglinideCitalopram may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RepinotanThe metabolism of Repinotan can be decreased when combined with Citalopram.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Citalopram.Approved, Investigational
ResveratrolThe metabolism of Resveratrol can be decreased when combined with Citalopram.Approved, Experimental, Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Ribociclib is combined with Citalopram.Approved, Investigational
RifabutinThe metabolism of Citalopram can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Citalopram can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Citalopram can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Citalopram.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Citalopram.Approved
RiluzoleThe metabolism of Riluzole can be decreased when combined with Citalopram.Approved, Investigational
RisperidoneThe metabolism of Risperidone can be decreased when combined with Citalopram.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Citalopram.Investigational
RitonavirThe metabolism of Citalopram can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Citalopram is combined with Rizatriptan.Approved
RofecoxibCitalopram may increase the antiplatelet activities of Rofecoxib.Approved, Investigational, Withdrawn
RolapitantThe metabolism of Citalopram can be decreased when combined with Rolapitant.Approved, Investigational
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Citalopram.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Citalopram.Vet Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Citalopram.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Citalopram.Approved
RosiglitazoneCitalopram may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Citalopram.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Citalopram.Approved
RucaparibThe serum concentration of Citalopram can be increased when it is combined with Rucaparib.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Citalopram.Approved
SafrazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Safrazine.Withdrawn
SalbutamolSalbutamol may increase the QTc-prolonging activities of Citalopram.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Citalopram.Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
SarilumabThe therapeutic efficacy of Citalopram can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinCitalopram may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Citalopram.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Citalopram.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Citalopram is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Citalopram.Investigational
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Citalopram.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Citalopram.Approved, Investigational, Withdrawn
SertralineThe serum concentration of Citalopram can be increased when it is combined with Sertraline.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Citalopram.Approved, Vet Approved
SildenafilThe metabolism of Citalopram can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Citalopram.Approved
SiltuximabThe serum concentration of Citalopram can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Citalopram can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Citalopram.Approved
SitagliptinCitalopram may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Citalopram.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Citalopram.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Sotalol.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Citalopram.Experimental
St. John's WortThe serum concentration of Citalopram can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Citalopram can be increased when it is combined with Stiripentol.Approved
SufentanilSufentanil may increase the serotonergic activities of Citalopram.Approved, Investigational
SulfadiazineCitalopram may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Citalopram.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Citalopram.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Citalopram.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Citalopram.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Citalopram is combined with Sumatriptan.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Citalopram.Approved, Investigational
TacrineThe metabolism of Tacrine can be decreased when combined with Citalopram.Investigational, Withdrawn
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Citalopram.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Citalopram resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Citalopram.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Citalopram.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Citalopram is combined with Tapentadol.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Citalopram.Approved, Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Citalopram.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Citalopram.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Citalopram can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Citalopram.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Citalopram.Approved
TemafloxacinThe metabolism of Temafloxacin can be decreased when combined with Citalopram.Withdrawn
TemazepamThe metabolism of Temazepam can be decreased when combined with Citalopram.Approved, Investigational
TeniposideThe metabolism of Teniposide can be decreased when combined with Citalopram.Approved
TerbinafineThe metabolism of Citalopram can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Citalopram.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Citalopram.Approved, Withdrawn
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Citalopram.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Citalopram.Approved, Investigational
Testosterone cypionateThe metabolism of Testosterone cypionate can be decreased when combined with Citalopram.Approved
Testosterone enanthateThe metabolism of Testosterone enanthate can be decreased when combined with Citalopram.Approved
Testosterone undecanoateThe metabolism of Testosterone undecanoate can be decreased when combined with Citalopram.Approved, Investigational
TetrabenazineThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Citalopram.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Citalopram.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Citalopram.Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Citalopram.Approved, Investigational, Withdrawn
TheobromineThe metabolism of Theobromine can be decreased when combined with Citalopram.Approved, Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Citalopram.Approved
ThiabendazoleThe metabolism of Thiabendazole can be decreased when combined with Citalopram.Approved, Vet Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Citalopram.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Thiazinam is combined with Citalopram.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Citalopram.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Citalopram.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Citalopram is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Citalopram.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Citalopram.Approved, Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Citalopram.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Citalopram.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Citalopram.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Citalopram.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Citalopram.Approved, Investigational
TiclopidineThe serum concentration of Citalopram can be increased when it is combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Citalopram.Vet Approved
TilidineTilidine may increase the serotonergic activities of Citalopram.Experimental
TimololThe metabolism of Timolol can be decreased when combined with Citalopram.Approved
TioclomarolCitalopram may increase the anticoagulant activities of Tioclomarol.Experimental
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Citalopram.Approved
TipranavirThe metabolism of Citalopram can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Citalopram.Approved, Investigational
TocilizumabThe serum concentration of Citalopram can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Citalopram.Approved, Investigational
TolazamideCitalopram may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Citalopram.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Citalopram.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Citalopram.Approved
TolperisoneThe metabolism of Tolperisone can be decreased when combined with Citalopram.Approved, Investigational
TolterodineTolterodine may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
TopiramateThe serum concentration of Citalopram can be increased when it is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Citalopram.Approved, Investigational
ToremifeneThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Citalopram.Approved, Investigational
TramadolCitalopram may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TranylcypromineThe serum concentration of Citalopram can be increased when it is combined with Tranylcypromine.Approved, Investigational
TrazodoneCitalopram may increase the serotonergic activities of Trazodone.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Citalopram.Approved, Investigational, Nutraceutical
TriamtereneThe metabolism of Triamterene can be decreased when combined with Citalopram.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Citalopram.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Citalopram.Vet Approved
TrichlormethiazideCitalopram may increase the hyponatremic activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Citalopram.Approved
TrifluoperazineThe metabolism of Trifluoperazine can be decreased when combined with Citalopram.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Citalopram.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Citalopram.Approved, Vet Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Citalopram.Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Citalopram.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Citalopram.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Citalopram.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Citalopram.Approved, Vet Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Citalopram.Investigational, Withdrawn
TropisetronTropisetron may increase the serotonergic activities of Citalopram.Approved, Investigational
UlipristalThe metabolism of Ulipristal can be decreased when combined with Citalopram.Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Citalopram.Approved
VadimezanThe metabolism of Vadimezan can be decreased when combined with Citalopram.Investigational
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Citalopram.Approved, Investigational
ValdecoxibCitalopram may increase the antiplatelet activities of Valdecoxib.Approved, Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Citalopram.Approved, Investigational
VandetanibThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Citalopram.Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Citalopram.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Citalopram.Approved
VenlafaxineVenlafaxine may increase the serotonergic activities of Citalopram.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Citalopram.Experimental
VerapamilThe metabolism of Citalopram can be decreased when combined with Verapamil.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Citalopram.Approved, Investigational
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Citalopram.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Citalopram.Approved
VilazodoneCitalopram may increase the serotonergic activities of Vilazodone.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Citalopram.Approved
VincristineThe excretion of Vincristine can be decreased when combined with Citalopram.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Citalopram.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Citalopram.Experimental
VoriconazoleThe serum concentration of Citalopram can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
VortioxetineCitalopram may increase the serotonergic activities of Vortioxetine.Approved, Investigational
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Citalopram.Approved, Investigational
WarfarinThe metabolism of Warfarin can be decreased when combined with Citalopram.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Citalopram.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Citalopram.Vet Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Citalopram.Approved, Investigational, Vet Approved
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Citalopram.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Citalopram.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Citalopram.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Citalopram.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Citalopram.Approved, Investigational, Withdrawn
ZimelidineCitalopram may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Citalopram.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Citalopram is combined with Zolmitriptan.Approved, Investigational
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Citalopram.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Citalopram.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Citalopram.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Citalopram.Approved, Investigational, Withdrawn
ZucapsaicinThe serum concentration of Citalopram can be increased when it is combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid St.John's Wort.
  • Take without regard to meals.

References

Synthesis Reference

Hans Petersen, "Method for the preparation of citalopram." U.S. Patent US6229026, issued December, 1992.

US6229026
General References
  1. Sindrup SH, Bjerre U, Dejgaard A, Brosen K, Aaes-Jorgensen T, Gram LF: The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther. 1992 Nov;52(5):547-52. [PubMed:1424428]
  2. Atmaca M, Kuloglu M, Tezcan E, Semercioz A: The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. Int J Impot Res. 2002 Dec;14(6):502-5. [PubMed:12494286]
  3. Andersen G, Vestergaard K, Riis JO: Citalopram for post-stroke pathological crying. Lancet. 1993 Oct 2;342(8875):837-9. [PubMed:8104273]
  4. Clayton A, Keller A, McGarvey EL: Burden of phase-specific sexual dysfunction with SSRIs. J Affect Disord. 2006 Mar;91(1):27-32. Epub 2006 Jan 20. [PubMed:16430968]
  5. Baumann P: Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int Clin Psychopharmacol. 1996 Mar;11 Suppl 1:5-11. [PubMed:8732438]
  6. Hyttel J, Bogeso KP, Perregaard J, Sanchez C: The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm Gen Sect. 1992;88(2):157-60. [PubMed:1632943]
  7. Caccia S: Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet. 1998 Apr;34(4):281-302. [PubMed:9571301]
  8. MSDS citalopram [Link]
External Links
Human Metabolome Database
HMDB0005038
KEGG Drug
D07704
KEGG Compound
C07572
PubChem Compound
2771
PubChem Substance
46508746
ChemSpider
2669
BindingDB
25870
ChEBI
77397
ChEMBL
CHEMBL549
Therapeutic Targets Database
DAP000118
PharmGKB
PA449015
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Citalopram
ATC Codes
N06AB04 — Citalopram
AHFS Codes
  • 28:16.04.20 — Selective-serotonin Reuptake Inhibitors
FDA label
Download (148 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedSupportive CareMajor Depressive Disorder (MDD) / Neoplasms1
0Not Yet RecruitingTreatmentDepression; Psychoneurotic / Pain1
0RecruitingTreatmentMajor Depressive Disorder (MDD)1
1CompletedNot AvailableAutism Spectrum Conditions/Disorders1
1CompletedNot AvailableDepression / Human Immunodeficiency Virus (HIV)1
1CompletedNot AvailableHealthy Volunteers7
1CompletedBasic ScienceAlcohol Dependence1
1CompletedBasic ScienceDepression1
1CompletedTreatmentDepressive Disorder and Anxiety Disorders1
1CompletedTreatmentHealthy Volunteers4
1CompletedTreatmentHealthy Young and Older Adults1
1RecruitingBasic ScienceUnipolar Depression1
1, 2WithdrawnTreatmentAcute Coronary Syndromes (ACS)1
2Active Not RecruitingTreatmentCitalopram / Major Depressive Disorder (MDD)1
2Active Not RecruitingTreatmentMajor Depressive Disorder (MDD)1
2CompletedNot AvailableNormal Volunteers1
2CompletedTreatmentAlcohol Abuse / Alcoholism1
2CompletedTreatmentAttention Deficit and Disruptive Behavior Disorders / Attention Deficit Disorder With Hyperactivity (ADHD) / Mental Disorders Diagnosed in Childhood / Moods Disorders1
2CompletedTreatmentAutistic Disorder1
2CompletedTreatmentBereavement / Complicated Grief1
2CompletedTreatmentBorderline Personality Disorder (BPD) / Depression Not Otherwise Specified / Dysthymic Disorder / Major Depressive Disorder (MDD)1
2CompletedTreatmentChorea / Executive Dysfunction / Huntington's Disease (HD)1
2CompletedTreatmentDementias1
2CompletedTreatmentDependence, Cocaine3
2CompletedTreatmentDepression2
2CompletedTreatmentDepression / Major Depressive Disorder (MDD)2
2CompletedTreatmentIrritable Bowel Syndrome (IBS)1
2CompletedTreatmentMajor Depressive Disorder (MDD)1
2CompletedTreatmentStroke, Ischemic / Strokes1
2Unknown StatusTreatmentCocaine Abuse / Opiate Dependence1
2WithdrawnNot AvailableDepression1
2, 3CompletedTreatmentBipolar Disorder (BD) / Depression, Bipolar1
2, 3CompletedTreatmentDepression1
2, 3CompletedTreatmentDepression / Suicide, Attempted1
2, 3CompletedTreatmentMajor Depressive Disorder (MDD)1
2, 3Unknown StatusTreatmentAbdominal Pain (AP) / Feeling Anxious1
3CompletedPreventionDepression / Hepatitis C Viral Infection / Human Immunodeficiency Virus (HIV) Infections1
3CompletedSupportive CareBone Mineral Density Quantitative Trait Locus 71
3CompletedSupportive CareCancer, Breast / Menopausal Hot Flushes / Psychosocial Effects of Cancer and Its Treatment1
3CompletedTreatmentAcute Agitation / Alzheimer's Disease (AD)1
3CompletedTreatmentAlzheimer's Disease (AD) / Dementia, Vascular / Dementias1
3CompletedTreatmentDepression / Depressive Disorders1
3CompletedTreatmentMajor Depressive Disorder (MDD)3
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3WithdrawnTreatmentMajor Depressive Disorder (MDD)1
4Active Not RecruitingTreatmentSchizophrenic Disorders / Schizophreniform Disorder1
4CompletedNot AvailableAlcohol Use Disorder (AUD) / Major Depressive Disorder (MDD)1
4CompletedNot AvailableInjuries, Whiplash1
4CompletedHealth Services ResearchObsessive Compulsive Disorder (OCD)1
4CompletedOtherHealthy Controls / Major Depressive Disorder (MDD)1
4CompletedPreventionDepression / Hepatitis C Viral Infection1
4CompletedSupportive CareFriedreich's Ataxia1
4CompletedTreatmentAntidepressant Activity in Healthy Volunteers1
4CompletedTreatmentDementias2
4CompletedTreatmentDepression5
4CompletedTreatmentDepression / Mild Cognitive Impairment (MCI)1
4CompletedTreatmentDepression / Traumatic Brain Injury (TBI)1
4CompletedTreatmentDepressive illness1
4CompletedTreatmentFrontotemporal Dementia1
4CompletedTreatmentMajor Depressive Disorder (MDD)3
4CompletedTreatmentNegative Symptoms / Schizophrenic Disorders1
4CompletedTreatmentSchizophrenic Disorders1
4CompletedTreatmentSleep disorders and disturbances1
4Not Yet RecruitingTreatmentGastro-esophageal Reflux Disease (GERD)1
4RecruitingNot AvailableDepressive Disorders / Lactation1
4RecruitingBasic ScienceBipolar Disorder (BD)1
4RecruitingBasic ScienceMajor Depressive Disorder (MDD)1
4RecruitingTreatmentAnxiety Disorders / Obsessive-Compulsive Disorder (OCD) / Psychiatric Disorder NOS1
4RecruitingTreatmentChest Pain Rule Out Myocardial Infarction1
4RecruitingTreatmentStrokes1
4TerminatedTreatmentAcute Coronary Syndromes (ACS) / Major Depressive Episode1
4TerminatedTreatmentDepression / Relapsing Remitting Multiple Sclerosis (RRMS)1
4TerminatedTreatmentMajor Depressive Disorder With Psychotic Features1
4Unknown StatusNot AvailableMajor Depressive Disorder (MDD)1
4Unknown StatusTreatmentBorderline Personality Disorder (BPD) / Suicide1
4Unknown StatusTreatmentDepression1
4Unknown StatusTreatmentMajor Depressive Disorder (MDD)2
4Unknown StatusTreatmentSchizophrenic Disorders1
4WithdrawnTreatmentComorbidity / Feeling Anxious / Major Depressive Disorder (MDD)1
Not AvailableActive Not RecruitingNot AvailableCancer, Breast / Depression / Menopausal Hot Flushes / Psychosocial Effects of Cancer and Its Treatment1
Not AvailableCompletedNot AvailableAcute Kidney Injury (AKI) / Depression1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedNot AvailableMajor Depressive Disorder (MDD) / Major Depressive Disorder, Bipolar I and Bipolar II1
Not AvailableCompletedBasic ScienceAlcohol Dependence / Alcoholism / Stress1
Not AvailableCompletedBasic ScienceAntidepressive Agents, Second-Generation1
Not AvailableCompletedBasic ScienceCognitive Performance in Major Depression1
Not AvailableCompletedBasic ScienceHealthy Volunteers1
Not AvailableCompletedBasic ScienceMDMA Mechanism of Action1
Not AvailableCompletedBasic ScienceMajor Depressive Disorder (MDD)1
Not AvailableCompletedOtherHealthy Young and Elderly Volunteers1
Not AvailableCompletedTreatmentAlzheimer's Disease (AD)1
Not AvailableCompletedTreatmentCancers / Depression / Palliative Care / Psychiatric Disorder NOS1
Not AvailableCompletedTreatmentCardiovascular Disease (CVD) / Heart Diseases1
Not AvailableCompletedTreatmentDepression2
Not AvailableCompletedTreatmentDepression / Feeling Anxious1
Not AvailableCompletedTreatmentDepression / Major Depressive Disorder (MDD)1
Not AvailableCompletedTreatmentSchizophrenic Disorders1
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1
Not AvailableRecruitingNot AvailableObesity, Morbid1
Not AvailableRecruitingOtherObsessive-Compulsive Disorder (OCD)1
Not AvailableRecruitingTreatmentAlcohol-Related Disorders / Brain Injury / Chronic Diseases / Depression / Mild Cognitive Impairment (MCI) / Pain / Posttraumatic Stress Disorders / Quality of Life / Substance-Related Disorders / Suicidal Ideation / Wounds and Injuries1
Not AvailableTerminatedTreatmentDepression / Depressive Disorders / Moods Disorders1
Not AvailableUnknown StatusNot AvailableFatigue Syndrome, Chronic / Fibromyalgia / Rheumatoid Arthritis1
Not AvailableUnknown StatusNot AvailablePrurigo Nodularis1
Not AvailableUnknown StatusTreatmentAsthma Bronchial1
Not AvailableUnknown StatusTreatmentTraumatic Brain Injury (TBI)1
Not AvailableUnknown StatusTreatmentTreatment Resistant Depression (TRD)1
Not AvailableWithdrawnHealth Services ResearchShort Bowel Syndrome (SBS)1

Pharmacoeconomics

Manufacturers
  • Alphapharm party ltd
  • Forest laboratories inc
  • Apotex inc richmond hill
  • Aurobindo pharma ltd inc
  • Roxane laboratories inc
  • Silarx pharmaceuticals inc
  • Biovail laboratories international srl
  • Actavis elizabeth llc
  • Amneal pharmaceuticals ny llc
  • Apotex inc etobicoke site
  • Aurobindo pharma ltd
  • Caraco pharmaceutical laboratories ltd
  • Corepharma llc
  • Dr reddys laboratories ltd
  • Epic pharma llc
  • Glenmark generics ltd
  • Invagen pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Matrix laboratories inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Natco pharma ltd
  • Pliva inc
  • Sandoz inc
  • Taro pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Torrent pharmaceuticals ltd
  • Watson laboratories inc
Packagers
  • Actavis Group
  • Advanced Pharmaceutical Services Inc.
  • Aidarex Pharmacuticals LLC
  • Amerisource Health Services Corp.
  • Amkas Laboratories Inc.
  • Amneal Pharmaceuticals
  • Apotex Inc.
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Aurobindo Pharma Ltd.
  • Aurolife Pharma LLC
  • Blu Pharmaceuticals LLC
  • Bryant Ranch Prepack
  • Camber Pharmaceuticals Inc.
  • Caraco Pharmaceutical Labs
  • Cardinal Health
  • Cipla Ltd.
  • Cobalt Pharmaceuticals Inc.
  • Comprehensive Consultant Services Inc.
  • Corepharma LLC
  • Coupler Enterprises Inc.
  • Cypress Pharmaceutical Inc.
  • Dept Health Central Pharmacy
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Doctor Reddys Laboratories Ltd.
  • Eon Labs
  • Forest Laboratories Inc.
  • Forest Pharmaceuticals
  • Glenmark Generics Ltd.
  • Greenstone LLC
  • Heartland Repack Services LLC
  • Innoviant Pharmacy Inc.
  • International Laboratories Inc.
  • InvaGen Pharmaceuticals Inc.
  • Inwood Labs
  • Kali Laboratories Inc.
  • Lake Erie Medical and Surgical Supply
  • Legacy Pharmaceuticals Packaging LLC
  • Lundbeck Inc.
  • Major Pharmaceuticals
  • Matrix Laboratories Ltd.
  • Medvantx Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Perrigo Co.
  • Physicians Total Care Inc.
  • Pliva Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Rebel Distributors Corp.
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Roxane Labs
  • Silarx Pharmaceuticals
  • Southwood Pharmaceuticals
  • Stat Rx Usa
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals
  • Va Cmop Dallas
  • Vangard Labs Inc.
  • W and D Distributing Co.
Dosage forms
FormRouteStrength
TabletOral20 mg
TabletOral40 mg
TabletOral10 mg/1
TabletOral20 mg/1
TabletOral40 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral20 mg/1
SolutionOral10 mg/5mL
TabletOral40 mg/301
Tablet, film coatedOral40 mg/1
TabletOral30 mg
TabletOral10 mg
Kit
Prices
Unit descriptionCostUnit
Citalopram Hydrobromide 10 mg/5ml Solution 240ml Bottle122.28USD bottle
Celexa 40 mg tablet3.88USD tablet
Celexa 20 mg tablet3.72USD tablet
Celexa 10 mg tablet3.57USD tablet
Citalopram Hydrobromide 40 mg tablet2.89USD tablet
Citalopram Hydrobromide 20 mg tablet2.8USD tablet
Citalopram Hydrobromide 10 mg tablet2.68USD tablet
Citalopram hbr 40 mg tablet2.53USD tablet
Citalopram hbr 20 mg tablet2.43USD tablet
Citalopram hbr 10 mg tablet2.33USD tablet
Celexa 20 mg Tablet1.47USD tablet
Celexa 40 mg Tablet1.47USD tablet
Ctp 30 30 mg Tablet0.99USD tablet
Apo-Citalopram 20 mg Tablet0.82USD tablet
Apo-Citalopram 40 mg Tablet0.82USD tablet
Citalopram 20 mg Tablet0.82USD tablet
Citalopram 40 mg Tablet0.82USD tablet
Citalopram-Odan 20 mg Tablet0.82USD tablet
Citalopram-Odan 40 mg Tablet0.82USD tablet
Co Citalopram 20 mg Tablet0.82USD tablet
Co Citalopram 40 mg Tablet0.82USD tablet
Jamp-Citalopram 20 mg Tablet0.82USD tablet
Jamp-Citalopram 40 mg Tablet0.82USD tablet
Mint-Citalopram 20 mg Tablet0.82USD tablet
Mint-Citalopram 40 mg Tablet0.82USD tablet
Mylan-Citalopram 20 mg Tablet0.82USD tablet
Mylan-Citalopram 40 mg Tablet0.82USD tablet
Ng Citalopram 20 mg Tablet0.82USD tablet
Ng Citalopram 40 mg Tablet0.82USD tablet
Novo-Citalopram 20 mg Tablet0.82USD tablet
Novo-Citalopram 40 mg Tablet0.82USD tablet
Phl-Citalopram 20 mg Tablet0.82USD tablet
Phl-Citalopram 40 mg Tablet0.82USD tablet
Pms-Citalopram 20 mg Tablet0.82USD tablet
Pms-Citalopram 40 mg Tablet0.82USD tablet
Ran-Citalo 20 mg Tablet0.82USD tablet
Ran-Citalo 40 mg Tablet0.82USD tablet
Ran-Citalopram 20 mg Tablet0.82USD tablet
Ran-Citalopram 40 mg Tablet0.82USD tablet
Ratio-Citalopram 20 mg Tablet0.82USD tablet
Ratio-Citalopram 40 mg Tablet0.82USD tablet
Sandoz Citalopram 20 mg Tablet0.82USD tablet
Sandoz Citalopram 40 mg Tablet0.82USD tablet
Pms-Citalopram 10 mg Tablet0.47USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2353693No2003-07-222021-07-24Canada
CA2049368No2001-10-232011-08-16Canada

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)182-183 °C[L1355]
water solubilitySparingly soluble FDA label
logP3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00588 mg/mLALOGPS
logP3.58ALOGPS
logP3.76ChemAxon
logS-4.7ALOGPS
pKa (Strongest Basic)9.78ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area36.26 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity94.02 m3·mol-1ChemAxon
Polarizability35.4 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9966
Blood Brain Barrier+0.9729
Caco-2 permeable+0.6099
P-glycoprotein substrateSubstrate0.7597
P-glycoprotein inhibitor INon-inhibitor0.6361
P-glycoprotein inhibitor IIInhibitor0.9789
Renal organic cation transporterInhibitor0.6993
CYP450 2C9 substrateNon-substrate0.8401
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.5054
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5223
Ames testNon AMES toxic0.7602
CarcinogenicityNon-carcinogens0.7452
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9054 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7735
hERG inhibition (predictor II)Inhibitor0.8994
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0a4i-9110000000-5b1fde1b7a58929c7f2d
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0009000000-589e7ae88aee7da0e0bd
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0029000000-8fd40dc922da5ab2c8b0
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0291000000-c60cbea4e4e6acbb4599
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00l2-0290000000-f2131534473e56b3c8a7
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00mk-0390000000-e6cd61150feeca1d2867
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0291000000-ff658bd6b54adccbaf03
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0009000000-67fa40aabd862948aaf3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0129000000-60abdaff2f5d8f72e271
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0bt9-0981000000-1eba423765a46f1dd6b9
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0980000000-514f2e0bb73903b25b90
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0970000000-f27f46e3a573498d9f9b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0980000000-5ba355c707bc5008c067
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0009000000-a115136f2084cc2a6a47
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0129000000-474ae50db9e74e5a31be
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0bt9-0981000000-011dbb85d8e791486397
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0970000000-99aedc452f996b9c9113
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0980000000-c8734dde2a469350af7c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0970000000-cff11d70160f94e8fc2e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0391000000-e7862ea10a18e5771adc
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0980000000-d24616414bd7fc5e1182
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0970000000-1c68a33d62afa4612071
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0394000000-f3c86fb3bf5bc7669307
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0390000000-5c227e85878c48f06a42
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004i-0239000000-900cc91bba3c1f9f3674
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylbutylamines. These are compounds containing a phenylbutylamine moiety, which consists of a phenyl group substituted at the fourth carbon by an butan-1-amine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylbutylamines
Direct Parent
Phenylbutylamines
Alternative Parents
Isocoumarans / Fluorobenzenes / Aralkylamines / Aryl fluorides / Trialkylamines / Oxacyclic compounds / Nitriles / Dialkyl ethers / Organopnictogen compounds / Organofluorides
show 1 more
Substituents
Phenylbutylamine / Isocoumaran / Fluorobenzene / Halobenzene / Aralkylamine / Aryl halide / Aryl fluoride / Tertiary amine / Tertiary aliphatic amine / Oxacycle
show 15 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organofluorine compound, tertiary amino compound, 2-benzofurans, nitrile, cyclic ether (CHEBI:77397)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Eriksson E, Engberg G, Bing O, Nissbrandt H: Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain. Neuropsychopharmacology. 1999 Mar;20(3):287-96. [PubMed:10063489]
  2. Maines LW, Keck BJ, Smith JE, Lakoski JM: Corticosterone regulation of serotonin transporter and 5-HT1A receptor expression in the aging brain. Synapse. 1999 Apr;32(1):58-66. [PubMed:10188639]
  3. Vicentic A, Battaglia G, Carroll FI, Kuhar MJ: Serotonin transporter production and degradation rates: studies with RTI-76. Brain Res. 1999 Sep 11;841(1-2):1-10. [PubMed:10546982]
  4. Dugar A, Keck BJ, Maines LW, Miller S, Njai R, Lakoski JM: Compensatory responses in the aging hippocampal serotonergic system following neurodegenerative injury with 5,7-dihydroxytryptamine. Synapse. 2001 Feb;39(2):109-21. [PubMed:11180498]
  5. Dutta AK, Fei XS, Beardsley PM, Newman JL, Reith ME: Structure-activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogues: evaluation of O-and N-analogues and their binding to monoamine transporters. J Med Chem. 2001 Mar 15;44(6):937-48. [PubMed:11300876]
  6. Plenge P, Wiborg O: High- and low-affinity binding of S-citalopram to the human serotonin transporter mutated at 20 putatively important amino acid positions. Neurosci Lett. 2005 Aug 5;383(3):203-8. Epub 2005 Apr 25. [PubMed:15955412]
  7. Schloss P, Betz H: Heterogeneity of antidepressant binding sites on the recombinant rat serotonin transporter SERT1. Biochemistry. 1995 Oct 3;34(39):12590-5. [PubMed:7548008]
  8. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
  9. Zhong H, Hansen KB, Boyle NJ, Han K, Muske G, Huang X, Egebjerg J, Sanchez C: An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: kinetic binding studies with the ALI/VFL-SI/TT mutant. Neurosci Lett. 2009 Oct 25;462(3):207-12. doi: 10.1016/j.neulet.2009.07.030. Epub 2009 Jul 16. [PubMed:19616061]
  10. Rasmussen TN, Plenge P, Bay T, Egebjerg J, Gether U: A single nucleotide polymorphism in the human serotonin transporter introduces a new site for N-linked glycosylation. Neuropharmacology. 2009 Sep;57(3):287-94. doi: 10.1016/j.neuropharm.2009.05.009. Epub 2009 Jun 3. [PubMed:19500602]
  11. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Chanrion B, Mannoury la Cour C, Gavarini S, Seimandi M, Vincent L, Pujol JF, Bockaert J, Marin P, Millan MJ: Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction. Mol Pharmacol. 2008 Mar;73(3):748-57. Epub 2007 Dec 14. [PubMed:18083778]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Brosen K, Naranjo CA: Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol. 2001 Aug;11(4):275-83. [PubMed:11532381]
  2. Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54. [PubMed:10774624]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  4. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. [PubMed:9890159]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Brosen K, Naranjo CA: Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol. 2001 Aug;11(4):275-83. [PubMed:11532381]
  2. Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54. [PubMed:10774624]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  4. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. [PubMed:9890159]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369]
  2. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, Dose T, Ebinger M, Rosenhagen M, Kohli M, Kloiber S, Salyakina D, Bettecken T, Specht M, Putz B, Binder EB, Muller-Myhsok B, Holsboer F: Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008 Jan 24;57(2):203-9. doi: 10.1016/j.neuron.2007.11.017. [PubMed:18215618]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059]

Drug created on June 13, 2005 07:24 / Updated on May 21, 2018 17:37